

APP

Research Grade Aducanumab

Catalog No.	DHC12504A	Quantity:	100 µg
	DHC12504B		1.0 mg

Alternate Names: BART, BIIB-037, CAS: 1384260-65-4

Description: Aducanumab (brand name: Aduhelm) is an amyloid beta-directed monoclonal antibody that targets amyloid beta in the brains of people with Alzheimer's to reduce its buildup. Aducanumab is a monoclonal antibody (a protein that helps your immune system target other proteins), and it is designed to help your body remove something called amyloid beta from the brain. Amyloid beta is an important protein involved in the progression of Alzheimer's disease. Aducanumab is given intravenously (infused through a vein) monthly. Aducanumab does not cure Alzheimer's disease, but one (of two) large clinical studies suggests that aducanumab may slow the progression of the earliest symptoms of Alzheimer's disease.

UniProt ID (target): P05067

Target: Human Amyloid-beta precursor protein

Concentration: 1.0 mg/ml, lot specific

Source: XtenCHO

Isotype: Human IgG1 kappa

Formulation: 0.01M PBS buffer, pH 7.4

Purity: > 95% by SDS-PAGE

Endotoxin Level: ≤ 0.01 EU/µg by LAL analysis

Purification: Protein A/G affinity chromatography

INN: Aducanumab

Applications: Functional studies

Storage & Stability: Store at 2-8°C for up to 1 week, or in working aliquots at -20°C to -80°C for up to 1 year. **Avoid freeze/thaw cycles.**

NOT FOR HUMAN USE. FOR RESEARCH ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Cell Sciences[®]
65 Parker Street
Unit 11
Newburyport, MA 01950

Toll Free: 888-769-1246
Phone: 978-572-1070
Fax: 978-992-0298

E-mail: info@cellsciences.com
Website: www.cellsciences.com